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Background. The role of suppressive HSV therapy in women coinfected with HSV-2 and HIV-1 taking highly active antiretroviral
therapy (HAART) is unclear. Methods. 60 women with HIV-1/HSV-2 coinfection on HAART with plasma HIV-1 viral load (PVL)
≤75 copies/mL were randomized to receive acyclovir (N = 30) or no acyclovir (N = 3 0 ) .P V L ,g e n i t a lt r a c t( G T )H I V - 1 ,a n dG T
HSV were measured every 4 weeks for one year. Results. Detection of GT HIV-1 was not signiﬁcantly diﬀerent in the two arms (OR
1.23, P = 0.67), although this pilot study was underpowered to detect this diﬀerence. When PVL was undetectable, the odds of
detecting GT HIV were 0.4 times smaller in the acyclovir arm than in the control arm, though this was not statistically signiﬁcant
(P = 0.07). The odds of detecting GT HSV DNA in women receiving acyclovir were signiﬁcantly lower than in women in the
control group, OR 0.38, P<0.05. Conclusions. Chronic suppressive therapy with acyclovir in HIV-1/HSV-2-positive women on
HAARTsigniﬁcantlyreducesasymptomaticGTHSVshedding,thoughnotGTHIVsheddingorPVL.PVLwasstronglyassociated
with GT HIV shedding, reinforcing the importance of HAART in decreasing HIV sexual transmission.
1.Introduction
Herpes simplex virus type 2 (HSV-2) is the most common
cause of genital ulcer disease worldwide and has a seropreva-
lence of 60 to 90% in populations with human immun-
odeﬁciency virus type 1 (HIV-1) infection [1]. In persons
who are co-infected with HIV-1 and HSV-2, symptomatic
and asymptomatic reactivation of HSV-2 has been associated
with increased HIV-1 levels in plasma and the genital tract
(GT) [2–4].
Plasma and genital tract levels of HIV-1 have been
shown to signiﬁcantly decrease with administration of HSV
suppressive therapy, [5–7] though the role for HSV suppres-
sion in the prevention of HIV transmission is unclear. The
Partners in Prevention HSV/HIV Transmission Study, a large
randomized controlled trial of HIV-1/HSV-2 seropositive
individuals, showed that HSV suppression with acyclovir did
not reduce the risk of transmission of HIV-1 to the negative
partner, despite a reduction in plasma HIV-1 and a marked
reduction in the occurrence of genital ulcers due to HSV-2
[8]. The majority of studies examining the role of HSV sup-
pression in HIV-infected individuals have been conducted in
resource-limited settings in individuals not receiving highly
activeantiretroviraltherapy(HAART).OnestudyinBurkina
Faso did investigate the eﬀect of valacyclovir in HSV-2/
HIV-1-infected women receiving HAART and found no
signiﬁcant decrease in GT HIV shedding overall, although
a subanalysis of those women with detectable GT HIV at2 Infectious Diseases in Obstetrics and Gynecology
baseline showed a decrease in the presence and quantity of
detectable GT HIV [9].
We sought to explore the eﬀect of HSV suppressive
therapy with acyclovir on GT HIV shedding in women on
HAART through a randomized controlled trial pilot study.
GiventhehighratesofHSVamongHIV-infectedindividuals
and the increasing availability of antiretroviral therapy
worldwide, the results of this study may have implications
for management of this population.
2. Methods
2.1. Study Population and Procedures. Study participants
were recruited from The Miriam Hospital Immunology
Center (Providence, RI, USA). Eligible subjects included
all HIV-infected women over the age of 18 who were re-
ceiving stable HAART (the same antiretroviral therapy for
three months as part of a regimen recommended by the
Department of Health and Human Services guidelines) with
an undetectable PVL (<75 copies/mL) for at least three
months prior to enrollment, and who had a positive HSV-
2 serology by type-speciﬁc antibody. Women were excluded
if they were pregnant or wishing to become pregnant, if
they had had a hysterectomy or recent pelvic surgery, were
unwilling or unable to provide informed consent, or if
theywerealreadyreceivingchronicsuppressiveHSV-2medi-
cation. Women with recent but ﬁnite use of any anti-HSV-2
medication were not eligible until at least one month after
completing their medication course. Patients were referred
bytheir primary HIV provider,and eligible participants were
approached by a study nurse clinician and informed consent
wasobtained.ThisstudywasapprovedbytheMiriamHospi-
tal Institutional Review Board.
2.2. Trial Procedure. At the enrollment visit, 60 women (30
per arm) were randomized one-to-one using simple ran-
domization to receive suppressive acyclovir (800mg by
mouth twice daily) or no acyclovir; no placebo was given nor
was the study medication masked from the subjects or re-
search staﬀ. Following a baseline interview, a general phys-
ical and pelvic exam was performed and blood and GT
specimens were collected. All women had follow-up visits
scheduledmonthlyforoneyearforatotalof12visits.Ateach
follow-up visit, an interim history was obtained, focusing
on genital tract symptoms, intercurrent illnesses, and self-
reported medication adherence. A pelvic examination was
performed at each visit and paired GT and blood specimens
were obtained. Women were advised not to have sex, not
to douche, and not to insert any intravaginal products for
at least 48 hours prior to a study visit. Pelvic examinations
were deferred during menses, and visits were timed to occur
at mid-cycle. Women randomized to the observation arm
were able to receive intermittent anti-HSV-2 medications for
symptomatic outbreaks as needed.
2.3. Sample-Size Calculation. For the sample size calculation
of this pilot study, we assumed that HIV GT shedding would
be found in 30% of women not on HSV treatment [10, 11].
We expected that acyclovir treatment would reduce HIV-
1 RNA shedding. A sample size of 30 in each arm would
a l l o wd e t e c t i o no fad e c r e a s eo f2 0 %i nt h ed e t e c t i o no fa n y
HIV in the genital tract with 64% power and a decrease of
25% with 87% power, under a one-sided type-1 error rate
(alpha) of 0.10 and Fisher’s exact test. We recognize that the
methods used to analyze the data will have higher power,
since we will evaluate HIV quantity in addition to detection
and incorporate 11 longitudinal follow-up visits.
2.4. Laboratory Testing. HIV-1 infection was conﬁrmed us-
ing standard ELISA and Western Blot testing if not already
documented. HSV type-speciﬁc antibody testing was per-
formed to conﬁrm HSV-2 infection, using type-speciﬁc anti-
body (HerpeSelect, Focus diagnostics, Cypress, CA, USA).
GT secretions were collected using Tearﬂo ﬁlter paper from
theendocervix.Acervicalvaginallavage(CVL)wasobtained
using 10mL of normal saline for white blood cell counts,
performed using a hemacytometer. HSV DNA was identiﬁed
in the CVL using a laboratory developed real-time poly-
merase chain reaction (PCR) targeting a conserved region
of the pol gene of HSV 1 and 2. HIV-1 RNA testing was
performedonendocervicalspecimensandplasmawasquan-
tiﬁed by nucleic acid sequence based ampliﬁcation (NASBA,
bioM´ erieux Inc, Durham, North Carolina, USA), with a
lower limit of detection of 3,300 copies/mL for endocervical
specimens and 80 copies/mL for plasma. CVL specimens
were also tested for HIV RNA (lower limit of detection 80
copies/mL); however, these results were only incorporated in
the analysis if the endocervical result was missing (n = 3).
At the baseline visit, urine samples were tested for N.
gonorrhea and C. trachomatis by nucleic acid ampliﬁcation
(APTIMA GC/CT assay, Gen Probe Inc., San Diego, CA,
USA), and a blood sample was sent for syphilis screening
using an RPR (rapid plasma reagin) test. These tests were
repeated at follow-up visits if clinically indicated. A wet prep
was performed for T. vaginalis, bacterial vaginosis (BV), and
candida vaginitis at every study visit. T. vaginalis culture
(Trichomonas In Pouch TV, BioMed Diagnostics) was also
performed. A positive trichomonas result was recorded if
either or both wet mount and culture were positive. BV
was diagnosed using Amsel’s criteria. An ABA card P30 test
(AbacusDiagnostics,WestHills,CA,USA)wasusedtodetect
the presence of semen in genital secretions.
2.5. Study Outcomes. T h ep ri m a ryo u t c o m eo ft h i ss t u d yw a s
detection and amount of HIV-1 RNA in the genital tract.
Secondary outcomes were the detection of GT HSV-2 DNA,
the detection and quantity of PVL, and self-reported adher-
ence to acyclovir and HAART. Outcomes for exploratory
analysis were presence of BV, GT WBC count, and adherence
to HAART. We evaluated both the presence and quantity
of HIV-1 RNA in the GT and plasma. Since HIV-1 RNA
concentrations have a lower detection limit and highly
skewed distribution, HIV-1 RNA was analyzed as detectable
versus undetectable. For a quantitative analysis of HIV-1
RNA outcomes, PVL values were placed into one of ﬁve
ordinal groups: undetectable (≤80 copies/mL), between 80Infectious Diseases in Obstetrics and Gynecology 3
and 1,000; between 1,000 and 10,000; between 10,000 and
100,000;morethan>100,000copies/mL.GTHIV-1RNAob-
servations were grouped similarly except the undetectable
group was deﬁned as ≤3,300 copies/mL, and the second
ordinal group contained observations between 3,300 and
10,000 copies/mL.
2.6. Data Analysis. Regression models for longitudinal data
were used to evaluate the eﬀect of acyclovir on the primary
and secondary outcomes. To compare the odds of detectable
PVL, GT HIV-1 RNA, and HSV-2 DNA by treatment arm,
linear models for binary outcomes were ﬁt using general-
ized estimating equations and exchangeable within-subject
correlation structure, and robust standard errors were used
to construct 95% conﬁdence intervals (CI). To compare the
ordinal quantity of HIV-1 RNA in the plasma and in the
GT by arm, mixed-eﬀects proportional odds models were
used,withobservationsnestedwithinparticipant.Allmodels
assessing the treatment eﬀect were adjusted for the observed
value at the baseline visit. To evaluate associations with GT
HIV-1 shedding, such as the association between GT HIV-1
RNA and HSV detection, we included separate covariates for
within- and between-subject eﬀects of HSV and detectable
PVL and for treatment arm. The observation at baseline was
used for the cross-sectional, or between-subject, eﬀect, and
the observed change from baseline was used for the longi-
tudinal,orwithin-subject,eﬀect.Allanalyseswerecompleted
using R version 2.11.2.
3. Results
Sixty women met entry criteria, and thirty women were
enrolledineacharmofthestudy,contributing610visits(315
in the acyclovir arm, 295 in the control arm). The follow-
up rate was 83% overall (86% in acyclovir arm, 80% in the
control arm). Twenty-nine (48%) participants attended all
12 visits, 12 (20%) missed only one visit, 19 (32%) missed
two or more visits, of these 3 (5%) women only attended
the baseline visit. Two women became pregnant during the
study, one in each study arm; no study visits were performed
during their pregnancies. One symptomatic HSV outbreak
occurred in the control arm for which the subject received
routine anti-HSV treatment for 7 days.
The mean age was 44 years old and 35% of participants
were White, 38% were Black, and 18% were Hispanic
(Table 1).Sixty-ﬁvepercenthadmorethanoneriskfactorfor
HIV acquisition; the most common risks were ever having
sex with a man who was an injection drug user (63%) and
ever having sex with a man who was known to be HIV in-
fected (70%). Mean CD4 count at enrollment was 546,
and there were relatively few sexually transmitted infections
detected at enrollment other than BV (30%). Although
participants had to have undetectable PVL for at least 3
months prior to enrollment, 7 (12%) women had detectable
PVL (150 to 170,000 copies/mL) and 4 (7%) had detectable
GT HIV (8000 to 850,000 copies/mL) at the initial study
visit. Randomization was successful in balancing the arms
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Figure 1: (a) Prevalence of GT HIV sheddingin women on HAART
by arm. (b) Prevalence of GT HSV shedding in women on HAART
by arm.
by baseline characteristics; only one of the baseline charac-
teristics measured diﬀered by arm, ever having sex with an
HIV-infected male (P<0.05).
HAART regimens were also balanced between the two
groups at baseline, with the majority taking nonnucleoside
reverse transcriptase inhibitor (NNRTI) or protease-inhibi-
tor (PI-) based regimens. During the study, 3 participants
changed HAART regimens in the acyclovir group and 4
participants in the control group; none of these changes
involved switching classes of medications.
Cumulative clinical measures are presented in Table 2.
Over the course of the study, there were 7 episodes of tri-
chomoniasis in 4 women, 58 episodes of vaginal candidiasis
in 24 women, 180 episodes of BV in 35 women, and 30 epi-
sodes of positive semen tests in 17 women. In addition, there
were 40 episodes of HSV shedding in 24 women, 83 episodes
of detectable PVL in 30 women (14% of all visits), and 68
episodes of GT HIV shedding in 30 women (11% of all
visits).Fifty-eightpercentofwomenreportedmissingatleast
one ARV dose in the past two weeks; however, the percentage
of visits reporting nonadherence in the past two weeks was
17%. Five women, four in the acyclovir arm and one in the
control arm, were noticeably nonadherent to HAART and
had very high PVL. They account for 82% of visits with PVL
> 1000 copies (31/44 (70%) in acyclovir arm and 5/44 (11%)
in the control arm) and for 48% of visits with detectable GT
HIV (20/68 (29%) in acyclovir arm and 4/68 (6%) in the
control arm).
Figure 1(a) displays the percentage of women with de-
tectable GT HIV by arm at each visit. GT HIV-1 RNA shed-
ding was not signiﬁcantly diﬀerent in the acyclovir arm4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Baseline demographic and clinical characteristics.
Acyclovir (N = 30) No acyclovir (N = 30) Overall (N = 60) P value2
Age (mean) 45 (25–59) 43 (23–56) 44 0.53
Ethnicity
White 10 (33%) 11 (36%) 21 (35%) 0.43
Black 14 (47%) 9 (30%) 23 (38%)
Hispanic 5 (17%) 6 (20%) 11 (18%)
Other 1 (3%) 4 (13%) 5 (8%)
HIV risk factor
Ever injected drugs 15 (50%) 11 (37%) 26 (43%) 0.42
Ever had sex with male IDU 18 (60%) 20 (67%) 38 (63%) 0.79
Ever had sex with HIV-infected male 17 (57%) 25 (83%) 42 (70%) 0.05
Ever exchanged sex for drugs or money 6 (20%) 9 (30%) 15 (25%) 0.55
>1 HIV risk factor 18 (60%) 21 (70%) 39 (65%) 0.59
Baseline CD4 count: mean (range) 552 (196–1877) 539 (169–1600) 546 0.42
Baseline contraceptives 1 (3%) 0 (0%) 1 (2%) 1.0
HAART at baseline
NRTIs only 2 3 5 1.0
NRTI +NNRTI 15 15 30
N R T I + P I 1 21 12 3
Other: NNRTI +PI; integrase inhibitor 1 1 2
+ CCR5 inhibitor
Baseline Testing
Chlamydia 0 (0%) 0 (0%) 0 (0%) 1.0
Gonorrhea 0 (0%) 0 (0%) 0 (0%) 1.0
Syphilis 0 (0%) 0 (0%) 0 (0%) 1.0
Trichomonas 0 (0%) 1 (3%) 1 (2%) 1.0
BV 7 (23%) 11 (37%) 18 (30%) 0.40
Semen 2 (7%) 2 (6.7%) 4 (7%) 1.0
Asymptomatic HSV (PCR) 0 (0%) 3 (10%) 3 (5%) 0.24
Detectable baseline Plasma HIV 5 (17%) 2 (7%) 7 (12%) 0.43
Detectable baseline GT HIV1 3 (10%) 1 (3%) 4 (7%) 0.61
1One woman in the control arm had invalid baseline GT HIV.
2Categorical variables were tested using Fisher exact test, and continuous variables were tested using Wilcoxon rank sum test.
NOTE. IDU, injection drug user; HAART, highly active antiretroviral therapy; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NNRTIn o n -
nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; HSV, herpes simplex virus; PCR, polymerase chain reaction; GT, Genital Tract;B V ,b a c t e r i a l
vaginosis.
Table 2: Cumulative frequencies of clinical characteristics (visits 1–12).
Acyclovir (N = 315 visits) No acyclovir (N = 295 visits) Overall (N = 610 visits)
Trichomonas 1 (0.3%) 6 (2%) 7 (1%)
Candida 29 (9%) 29 (10%) 58 (10%)
Bacterial vaginosis 104 (33%) 76 (26%) 180 (30%)
S e m e nd e t e c t e d 1 9( 6 % ) 1 1( 4 % ) 3 0( 5 % )
>100 GT leukocytes 133 (42%) 153 (52%) 286 (47%)
Detectable asymptomatic HSV 10 (3%) 30 (10%) 40 (6%)
Detectable PVL 56 (18%) 26 (9%) 83 (14%)
Detectable GT HIV 40 (12%) 28 (9%) 68 (11%)
Missed ≥ 1 ARV dose in 2wk 61 (19%) 61 (20%) 122 (20%)
Missed ≥1 Acyclovir dose in 2wk 88 (31%) N/A N/A
NOTE. GT, Genital Tract; HSV, herpes simplex virus; PVL, plasma viral load; ARV, antiretroviral.Infectious Diseases in Obstetrics and Gynecology 5
Table 3: Primary and secondary outcomes analysis.
Acyclovir versus control OR (95% CI) P value
GT HIV-1 RNA
Detection 1.23 (0.47, 3.20) 0.67
Quantity 0.92 (0.28, 3.06) 0.90
Detection when PVL is undetectable 0.42 (0.17, 1.06) 0.07
Quantity when PVL is undetectable 0.34 (0.11, 1.05) 0.06
HSV DNA
Detection 0.38 (0.15, 0.99) <0.05
Plasma HIV-1 RNA
Detection 1.93 (0.66, 5.68) 0.23
Quantity 3.33 (0.61, 16.67) 0.17
Adherence
Three-day nonadherence to HAART 0.93 (0.47, 1.86) 0.84
Two-week nonadherence to HAART 1.30 (0.59, 2.87) 0.51
NOTE. GT, Genital Tract; RNA, ribonucleic acid; PVL, plasma viral load;
HSV, herpes simplex virus; DNA, deoxyribonucleic acid; HAART, highly
active antiretroviral therapy.
Table 4: Association between selected covariates and GT HIV-1
RNA shedding.
OR (95% CI) P value
Detectable HSV-2 DNA
Between-subject 5.68 (0.82, 39.18) 0.08
within-subject 3.35 (1.44, 7.81) <0.01
Bacterial Vaginosis
Between-subject 2.29 (1.01, 5.16) 0.05
within-subject 2.36 (1.10, 5.07) 0.03
GT WBC greater than 100
cells/mm3
Between-subject 2.11 (0.83, 5.39) 0.12
within-subject 1.84 (0.94, 3.60) 0.07
Missing ARV dose in past two weeks
Between-subject 2.37 (0.66, 8.45) 0.19
within-subject 2.16 (1.14, 4.10) 0.02
NOTE. GT, GT; RNA, ribonucleic acid; HSV, herpes simplex virus; DNA,
deoxyribonucleic acid; WBC, white blood cell; ARV, antiretroviral therapy.
compared to the control arm, when analyzed as a dichoto-
mous variable (OR=1.23, 95% CI=0.47 to 3.20) or as a
quantitative ordinal measure (OR=0.92, 95% CI=0.28 to
3.06) (Table 3). There were 34 visits with detectable GT HIV
viral load and undetectable PVL, 13 in acyclovir arm and 21
in the control arm. When PVL was undetectable, the eﬀect of
acyclovir on GT HIV shedding was not signiﬁcant, with the
odds of detecting GT HIV shedding 0.42 times lower in the
acyclovir arm versus the control arm (95% CI=0.17 to 1.06,
P = 0.07). The results using the ordinal GT HIV outcome
were similar (P = 0.06). The detection and quantity of PVL
and adherence to HAART, by 3-day and two-week measures,
were similar in both arms.
HSV shedding was signiﬁcantly lower in the acyclovir
arm compared to the control arm (OR 0.38, 95% CI=0.15
to 0.99, P<0.05) (Figure 1(b)). There was a signiﬁcant
and positive association between GT HIV-1 RNA and HSV
DNA detection, with the between-subject OR of HIV GT
shedding 5.68 times greater when HSV was detected (95%
CI=0.82 to 39.18, P = 0.08) and the within-subject OR of
HIV GT shedding 3.35 times greater when HSV DNA was
detected (95% CI=1.44 to 7.81, P<0.01). Other signiﬁcant
predictors of GT HIV shedding after controlling for PVL
includedBVandHAARTadherence;GTWBC>100cells/mL
was not signiﬁcant (Table 4).
With respect to the relationship of reported adherence
to measured outcomes, the 2-week adherence measure was
associatedwithbothplasmaandGTHIV,withthelongitudi-
nal, or within-subject, odds of detectable GT HIV 2.18 times
higher when participants were nonadherent (95% CI=1.02
to 4.65, P = 0.05) and odds of detectable PVL 2.4 times
higher when participants were non-adherent (95% CI=1.25
to 4.58, P<0.01). In the acyclovir arm, reported non-
adherence to acyclovir was highly correlated with reported
non-adherence to HAART (within- and between-subject
ORs ranging from 16.98 to 32.58). Detection of HSV was
signiﬁcantly associated with reported two-week non-adher-
ence to acyclovir.
4. Discussion
In this pilot randomized controlled trial study of 60 women,
chronic suppressive therapy with acyclovir in HIV-1/HSV-2
positive women on HAART was not found to signiﬁcantly
reduce HIV shedding in the genital tract. However, a subset
of 5 participants that was consistently non-adherent and
accounted for a signiﬁcant proportion of visits with high
PVL and detectable GT HIV may have skewed the results
since 4 out of the 5 individuals were in the acyclovir arm.
When estimating the eﬀect of acyclovir when PVL was unde-
tectable, participants in the acyclovir arm were 0.42 times
less likely to shed HIV in the genital tract (and 0.34 times
less likely to occupy a higher ordinal category of GT HIV
shedding) than those in the control arm. This study was not
powered to detect diﬀerences in this smaller subset and these
analyses did not reach statistical signiﬁcance (P = 0.07 and
P = 0.06, resp.). In other words, GT HIV shedding in the
absence of detectable PVL in women on HAART occurred
during a relatively small number of visits (6%), making it
diﬃcult to assess an additional impact of acyclovir.
We should emphasize that this is a pilot study, with the
intention to inform future randomized controlled trials on
this topic. We have, therefore, made further calculations as to
the sample size needed for such potential trials. We recently
reported GT shedding rates among women on HAART
with undetectable PVL at baseline of about 6% of visits in
samples from the endocervix and about 12% of visits in any
of the three samples taken simultaneously from the endo-
cervix,ectocervix,andvagina[12].Theseratesarelowerthan
those assumed in the sample size calculation for this pilot
study. With the study design used here, utilizing one baseline
and 11 follow-up visits and endocervix samples only, 102
participants would be required per arm (204 total) to detect6 Infectious Diseases in Obstetrics and Gynecology
a reduction by 50% in GT shedding and 473 per arm (946
total) to detect a reduction by 25% in GT shedding with
80% power and an alpha level of 0.05 [13]. If samples
were collected from the three subcompartments, 65 women
per arm (130 total) and 298 per arm (596 total) would be
required, respectively, to detect a 50% or 25% reduction in
GT shedding (power 80%, alpha 0.05).
With regards to secondary outcomes, acyclovir signiﬁ-
cantly reduced asymptomatic GT HSV shedding, and GT
HIV shedding was signiﬁcantly associated with GT HSV
shedding.Thissupportsthestrongassociationbetweenthese
two viruses which has been found in other studies [2–6, 8].
Although studies of HSV suppression in women not on
HAART have detected an eﬀect of HSV suppression on plas-
maHIVviralload,[7,8]wedidnotﬁndadiﬀerenceineither
the presence or quantity of PVL by study arm. We found that
although nonadherence to HIV medications was commonly
reported by participants, only a minority were persistently
nonadherent. Adherence to acyclovir was strongly associated
with adherence to HAART, published separately [14]. Lastly,
BV and GT WBCs were signiﬁcantly associated with GT HIV
shedding, which supports what has been shown in other
studies [15–17].
Our ﬁndings are congruent with those of Ouedraogo et
al. [9], who, with a similar sample size of 30 women per arm,
alsodidnotﬁndanoverallimpactofHSVsuppressiononthe
presence or quantity of GT HIV. They did, however, discover
a decrease in the proportion of visits with detectable GT HIV
andthequantityofGTHIVinthesubsetofpatientswhohad
GTHIVsheddingatbaseline.Oursubanalysisofparticipants
without detectable PVL may deﬁne a similar subgroup of
HIV-1/HSV-2 coinfected women who are more likely to shed
HIV in the genital tract in the absence of detectable PVL
and who may beneﬁt from HSV suppression. Our study has
several important distinctions from Ouedraogo et al. in that
it was performed in the developed world, with 12 visits over
a one-year period rather than 6 over 3 months time, with an
older cohort (mean age of 44 versus 33) and with lower rates
of overall HSV and HIV GT shedding.
Our study has several limitations. In general, the rates of
GT HIV shedding (11%) were lower than predicted (30%),
[10, 11] indicating that our study was underpowered to
detect relatively small diﬀerences in GT HIV shedding. Non-
adherence was high in this study, resulting in multiple visits
with elevated PVL as well as GT HIV, further limiting the
number of individuals with isolated HIV shedding in the
genital tract. Nonetheless, we believe our study population
reﬂects that of a typical HIV clinic in the United States. In
addition, although this was a pilot study, we were still able to
demonstrate an association between GT HSV and HIV shed-
dingaswellasaplausibleeﬀectonGTHIVsheddinginthose
women with undetectable PVL.
With an unchanging incidence of over 56,000 new
infections per year, [18] the prevalence of HIV-1 continues
to rise in the United States. Given the high rates of HSV-2
in this population and known interactions between these
two viruses, the prevalence of HIV-1/HSV-2 coinfection also
continues to increase, along with questions of optimal man-
agement in coinfected patients with asymptomatic HSV.
Prevention of HIV transmission remains a national priority,
[19] including prevention with those already known to be
HIV infected. The most signiﬁcant predictor of GT HIV
shedding in our study was a detectable PVL. Therefore, con-
necting known HIV-infected individuals to treatment and
maintaining them in care and on HAART is a top priority for
HIV prevention. Recent data underscore the importance of
HAART in controlling plasma viral load (and by extension
genital tract viral load) on an individual and community
level as a means of decreasing HIV transmission [20–22].
However, shedding of HIV in the genital tract does occur in
the absence of detectable PVL and HSV-2 plays a signiﬁcant
role in this. We and others have found that HSV suppression
decreases GT HIV shedding in a subset of patients. Addi-
tional research is required to elucidate further the speciﬁc
role of chronic HSV suppression in HIV prevention.
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